Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ramesh C Gupta MD

Neither a doctor nor a teaching hospital

Research payments

$453,213

92 payments

Through program year 2025, Ramesh C Gupta MD is reported as receiving $453,213 in research payments, across 92 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,109 5
2024 Research $7,858 6
2023 Research $54,108 37
2022 Research $106,529 20
2021 Research $79,629 2
2020 Research $156,810 12
2019 Research $43,169 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Horizon Therapeutics plc $181,359 4 payments
  2. AbbVie, Inc. $85,630 61 payments
  3. Amgen Inc. $61,122 2 payments
  4. Biogen, Inc. $46,900 1 payment
  5. Eli Lilly and Company $34,012 2 payments
  6. Pfizer Inc. $18,338 16 payments
  7. Novartis Pharmaceuticals Corporation $13,823 1 payment
  8. Celgene Corporation $10,179 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $1,850 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $131,361 2 payments
  2. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $71,739 54 payments
  3. P2b SLE $61,122 2 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care. $46,900 1 payment
  5. A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed By Long Term Evaluation of Efficacy and Safety of Ixekizumab Ly2439821 in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis $34,012 2 payments
  6. A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $32,729 1 payment
  7. Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $18,338 16 payments
  8. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Randomized Controlled Trial RCT $17,269 1 payment
  9. A Randomized, Double-Blind, Placebo Controlled, 3-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-2) $13,823 1 payment
  10. (CC-99677-AS-001) Phase 2 Ankylosing Spondylitis $9,544 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record